149 related articles for article (PubMed ID: 16434499)
1. Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7.
Fröhling S; Lipka DB; Kayser S; Scholl C; Schlenk RF; Döhner H; Gilliland DG; Levine RL; Döhner K
Blood; 2006 Feb; 107(3):1242-3. PubMed ID: 16434499
[No Abstract] [Full Text] [Related]
2. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.
Steensma DP; McClure RF; Karp JE; Tefferi A; Lasho TL; Powell HL; DeWald GW; Kaufmann SH
Leukemia; 2006 Jun; 20(6):971-8. PubMed ID: 16598306
[TBL] [Abstract][Full Text] [Related]
3. JAK2 V617F mutation is uncommon in non-Hodgkin lymphomas.
Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Lee JY; Yoo NJ; Lee SH
Leuk Lymphoma; 2006 Feb; 47(2):313-4. PubMed ID: 16321863
[TBL] [Abstract][Full Text] [Related]
4. Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation.
Mc Lornan DP; Percy MJ; Jones AV; Cross NC; Mc Mullin MF
Haematologica; 2005 Dec; 90(12):1696-7. PubMed ID: 16330446
[TBL] [Abstract][Full Text] [Related]
5. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.
Wolanskyj AP; Lasho TL; Schwager SM; McClure RF; Wadleigh M; Lee SJ; Gilliland DG; Tefferi A
Br J Haematol; 2005 Oct; 131(2):208-13. PubMed ID: 16197451
[TBL] [Abstract][Full Text] [Related]
6. The JAK2 V617F mutation in de novo acute myelogenous leukemias.
Lee JW; Kim YG; Soung YH; Han KJ; Kim SY; Rhim HS; Min WS; Nam SW; Park WS; Lee JY; Yoo NJ; Lee SH
Oncogene; 2006 Mar; 25(9):1434-6. PubMed ID: 16247455
[TBL] [Abstract][Full Text] [Related]
7. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.
Jelinek J; Oki Y; Gharibyan V; Bueso-Ramos C; Prchal JT; Verstovsek S; Beran M; Estey E; Kantarjian HM; Issa JP
Blood; 2005 Nov; 106(10):3370-3. PubMed ID: 16037387
[TBL] [Abstract][Full Text] [Related]
8. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
9. [Mutation of protein kinase JAK2 in polycythemia vera: new perspectives in physiopathology and therapy].
Marie I; Hervé F
Rev Med Interne; 2006 Jun; 27(6):473-7. PubMed ID: 16631280
[TBL] [Abstract][Full Text] [Related]
10. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.
Kralovics R; Teo SS; Li S; Theocharides A; Buser AS; Tichelli A; Skoda RC
Blood; 2006 Aug; 108(4):1377-80. PubMed ID: 16675710
[TBL] [Abstract][Full Text] [Related]
11. Screening of JAK2 V617F mutation in multiple myeloma.
Fiorini A; Farina G; Reddiconto G; Palladino M; Rossi E; Za T; Laurenti L; Giammarco S; Chiusolo P; Leone G; Sica S
Leukemia; 2006 Oct; 20(10):1912-3. PubMed ID: 16871278
[No Abstract] [Full Text] [Related]
12. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.
Lippert E; Boissinot M; Kralovics R; Girodon F; Dobo I; Praloran V; Boiret-Dupré N; Skoda RC; Hermouet S
Blood; 2006 Sep; 108(6):1865-7. PubMed ID: 16728702
[TBL] [Abstract][Full Text] [Related]
13. New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients.
Villeval JL; James C; Pisani DF; Casadevall N; Vainchenker W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):341-51. PubMed ID: 16810610
[TBL] [Abstract][Full Text] [Related]
14. The effect of the JAK2 V617F mutation on PRV-1 expression.
Mnjoyan Z; Yoon D; Li J; Delhommeau F; Afshar-Kharghan V
Haematologica; 2006 Mar; 91(3):411-2. PubMed ID: 16503546
[TBL] [Abstract][Full Text] [Related]
15. The V617F JAK2 mutation and the myeloproliferative disorders.
Percy MJ; McMullin MF
Hematol Oncol; 2005; 23(3-4):91-3. PubMed ID: 16285006
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders.
Greiner TC
Am J Clin Pathol; 2006 May; 125(5):651-3. PubMed ID: 16707363
[No Abstract] [Full Text] [Related]
17. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.
Campbell PJ; Griesshammer M; Döhner K; Döhner H; Kusec R; Hasselbalch HC; Larsen TS; Pallisgaard N; Giraudier S; Le Bousse-Kerdilès MC; Desterke C; Guerton B; Dupriez B; Bordessoule D; Fenaux P; Kiladjian JJ; Viallard JF; Brière J; Harrison CN; Green AR; Reilly JT
Blood; 2006 Mar; 107(5):2098-100. PubMed ID: 16293597
[TBL] [Abstract][Full Text] [Related]
18. A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples.
Sattler M; Walz C; Crowley BJ; Lengfelder E; Jänne PA; Rogers AM; Kuang Y; Distel RJ; Reiter A; Griffin JD
Blood; 2006 Feb; 107(3):1237-8. PubMed ID: 16434495
[No Abstract] [Full Text] [Related]
19. Absence of the JAK2 mutation V617F in CD34+ hematopoietic stem and progenitor cells from patients with BCR-ABL-positive CML in chronic phase and blast crisis.
Kronenwett R; Gräf T; Neumann F; Pechtel S; Steidl U; Diaz-Blanco E; Haas R
Leuk Res; 2006 Oct; 30(10):1323-4. PubMed ID: 16442619
[TBL] [Abstract][Full Text] [Related]
20. FLT3-TKD mutation in childhood acute myeloid leukemia.
Liang DC; Shih LY; Hung IJ; Yang CP; Chen SH; Jaing TH; Liu HC; Wang LY; Chang WH
Leukemia; 2003 May; 17(5):883-6. PubMed ID: 12750701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
